



truscreen  
a world without  
cervical cancer

## NZX/ASX Announcement

13 March 2024

### TruScreen Raises Additional NZ\$520,000 in Share Placement

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that further to the announcement of 4 March 2024 “Truscreen Raises Initial NZ\$500,000 in Share Placement”, the Company has received a further firm commitment from an investor for a Placement of 26,000,000 shares at NZ\$0.02 each to raise NZ\$520,000, before costs.

The shares will be issued under its existing 15% placement capacity. This Placement is in addition to the Oversubscription Bookbuild which will take place on 14<sup>th</sup> and 15<sup>th</sup> March 2024.

Tony Ho Chairman commented, “*we are pleased with the additional strong support for Truscreen. The rights issue closes today 13 March 2024 at 5pm NZ time*”.

In the event shareholders have not received application forms please contact the share registry Link Market Services:

[enquiries@linkmarketservices.co.nz](mailto:enquiries@linkmarketservices.co.nz) T +64 9 375 5998 or the Company Secretary, contact details below.

This announcement has been approved by the Board.

### Ends

Guy Robertson  
Company Secretary  
Tel: +61 407 983 270  
Email: [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Mr Martin Dillon  
Chief Executive Officer  
[martindillon@truscreen.com](mailto:martindillon@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

## About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra<sup>®</sup>, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140000\* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"<sup>®</sup>.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

*\*Based on Single Use Sensor sales.*